Origin (Diagnostic Equipment) key facts
as of Oct 2026- Manufacturer of genomic diagnostic tests designed to detect and monitor gastrointestinal diseases.
- Origin (Diagnostic Equipment) is valued at approximately $165.2M as of Oct 2026 (last reported valuation).
- It has raised $39.0M; the latest was Later Stage VC ($12.5M) in Dec 2024.
- Notable investors include CSVE Ventures, 2050 Capital, CPTLNYC, Chicago Booth Angels Network, Conan Capital — 7 tracked in total.
- Status: Privately Held (backing).
Origin (Diagnostic Equipment)'s last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·Watch Origin (Diagnostic Equipment): the Monday email on marks, rounds and moves
Origin (Diagnostic Equipment) funding rounds
No funding rounds for Origin (Diagnostic Equipment) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Origin (Diagnostic Equipment)
7Origin (Diagnostic Equipment) valuation
Origin (Diagnostic Equipment)'s last reported valuation was $165 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
Origin (Diagnostic Equipment) investors
7 investors are on record for Origin (Diagnostic Equipment), including CSVE Ventures, 2050 Capital, CPTLNYC and Chicago Booth Angels Network.
About Origin (Diagnostic Equipment)
Manufacturer of genomic diagnostic tests designed to detect and monitor gastrointestinal diseases. The company's platform offers rectal mucus sampling, multi-signal molecular analysis, and rapid test procedures, enabling healthcare providers to identify gastrointestinal conditions and support clinical decision-making.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2003
- Employees
- 42
- Website
- originsciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.